Rivastigmine transdermal - Teikoku Pharma USA
Latest Information Update: 07 Mar 2016
At a glance
- Originator Teikoku Pharma USA
- Class Antidementias; Phenylcarbamates; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Butyrylcholinesterase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 04 Mar 2016 Preclinical trials in Alzheimer's disease in USA (Transdermal) before March 2016
- 08 Oct 2015 Teikoku Pharma USA has patent protection for rivastigmine transdermal in USA